Scarica l'app Stockscreener
4.25
1.85%
-0.08
Dopo l'orario di chiusura:
4.25
Precedente Chiudi:
$4.33
Aprire:
$4.39
Volume 24 ore:
52,606
Relative Volume:
0.65
Capitalizzazione di mercato:
$39.32M
Reddito:
$6.16M
Utile/perdita netta:
$-25.59M
Rapporto P/E:
-1.4678
EPS:
-2.8954
Flusso di cassa netto:
$-24.93M
1 W Prestazione:
+3.41%
1M Prestazione:
-9.96%
6M Prestazione:
-51.98%
1 anno Prestazione:
-26.60%
Intervallo 1D:
$4.16
$4.6225
Intervallo di 1 settimana:
$4.07
$5.12
Portata 52W:
$3.58
$16.94
Cervomed Inc Stock (CRVO) Company Profile
Nome
Cervomed Inc
Settore
Industria
Telefono
(617) 744-4400
Indirizzo
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
4.25 | 39.32M | 6.16M | -25.59M | -24.93M | -2.8954 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-12-05 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-18 | Iniziato | Chardan Capital Markets | Buy |
| 2024-07-26 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cervomed Inc Borsa (CRVO) Ultime notizie
CervoMed Inc. (CRVO) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
CervoMed Inc. Annual Report 2025: Strategy, Key Terms, and Forward-Looking Statements for Age-Related Brain Disorders - Minichart
CRVO: Neflamapimod achieved robust, durable efficacy in DLB without AD co-pathology, advancing to Phase 3 - TradingView
CervoMed 10-K: $4.01M Grant Revenue; Net Loss $26.97M, $(2.98) EPS - TradingView
CRVO: Net loss widened to $27.0 million in 2025; ongoing operations depend on new capital - TradingView
CervoMed Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference - Sahm
CervoMed (CRVO) to Showcase Neflamapimod Advancements at AD/PD 2 - GuruFocus
CervoMed Announces Presentations at Upcoming AD/PD 2026 Scientific Conference - Bitget
Lewy body dementia has no drugs. New trial data spotlight a potential treatment - Stock Titan
CervoMed Inc neflamapimod selected by UK platform for ALS treatment assessment - Traders Union
Is CervoMed Inc. stock a good choice for value investorsWeekly Gains Report & Short-Term Trading Opportunity Alerts - Naître et grandir
CervoMed to Participate in Upcoming Investor Conferences - Sahm
D. Boral Capital Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - Defense World
Chardan Capital Maintains Buy Rating for CRVO | CRVO Stock News - GuruFocus
Biotech chasing age-related brain drugs makes March investor pitch - Stock Titan
CervoMed sets 50mg dose for phase 3 dementia trial By Investing.com - Investing.com Canada
CervoMed Finalizes Formulation and Dosing Regimen for Phase 3 Trial in Dementia with Lewy Bodies - geneonline.com
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com Australia
CervoMed Advances Neflamapimod With Phase 1 Completion - TipRanks
CervoMed (CRVO) Analyst Rating Update: Buy Rating Maintained by D. Boral Capital | CRVO Stock News - GuruFocus
Phase 3 neflamapimod dose set at 50 mg, CervoMed Inc. asserts - Traders Union
CervoMed Inc. Announces Successful Phase 1 Study of Stable Crystal Form of Neflamapimod and Planned Phase 3 Trial Dosing Regimen for Dementia with Lewy Bodies - Quiver Quantitative
CervoMed picks 50mg dose for dementia drug after Phase 1 study - Stock Titan
Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Guidance Update: Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
How do insiders feel about CervoMed Inc2025 Institutional Moves & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Stock Analysis: What is CervoMed Incs revenue forecastJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - baoquankhu1.vn
CRVOCervoMed Latest Stock News & Market Updates - Stock Titan
New ALS drug neflamapimod chosen for UK platform study - ALS News Today
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target - TipRanks
CervoMed’s neflamapimod selected for UK ALS trial platform By Investing.com - Investing.com Canada
CervoMed’s Neflamapimod Added to U.K. ALS Platform - TipRanks
CervoMed's neflamapimod selected for UK EXPERTS-ALS; first ALS dosing expected by end of 2026 - TradingView
Neflamapimod joins UK EXPERTS-ALS platform for ALS at CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Analyst Rating Maintained as "Buy" by D. Boral C - GuruFocus
CervoMed’s neflamapimod selected for UK ALS trial platform - Investing.com
CervoMed's Neflamapimod Chosen For UK EXPERTS-ALS Platform - Nasdaq
CervoMed (CRVO) Drug Candidate Joins EXPERTS-ALS Platform - GuruFocus
CervoMed's neflamapimod elected for inclusion in UK Experts-ALS Platform - marketscreener.com
CervoMed Inc. Announces Inclusion of Neflamapimod in EXPERTS-ALS Platform for ALS Trial - Quiver Quantitative
Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform - TradingView
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis - Yahoo Finance
Will CervoMed Inc. benefit from seasonalityJuly 2025 Setups & Smart Investment Allocation Tips - mfd.ru
Aug Summary: Is CervoMed Inc stock a good pick for beginnersWeekly Profit Recap & High Return Stock Watch Alerts - baoquankhu1.vn
Should You Buy CervoMed Inc (CRVO) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Form 4: Blackburn Kelly reports acquisition/exercise transactions in CRVO - Stock Titan
Is CervoMed Inc. stock a good pick for beginnersJuly 2025 Closing Moves & Growth Focused Stock Reports - mfd.ru
What’s the analyst consensus on CervoMed Inc.2025 Support & Resistance & High Accuracy Investment Signals - mfd.ru
CervoMed (NASDAQ:CRVO) Upgraded at Brookline Capital Management - Defense World
Cervomed Inc Azioni (CRVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):